Dimerix (DXB) Q4 2025 TU earnings summary

Executive summary

• Entered exclusive US licensing agreement for DMX-200 with Amicus Therapeutics, receiving US$30 million upfront and potential for up to US$590 million in total milestone payments plus royalties.

• Four licensing deals for DMX-200 now in place, with total potential upfront and milestone payments of ~AU$1.4 billion and over AU$65 million received to date.

• Continued progress in the ACTION3 Phase 3 clinical trial for FSGS, with 219 patients randomized/dosed and positive FDA feedback on primary endpoint.

• Strong cash position at AU$68.3 million as of 30 June 2025, supporting ongoing clinical and R&D activities.

Financial highlights

• Net operating cash inflows for the June quarter were AU$45.6 million, driven by licensing payments.

• Cash and cash equivalents increased from AU$17.0 million at 31 March 2025 to AU$68.3 million at 30 June 2025.

• Received AU$48 million upfront from Amicus and AU$4.2 million milestone from FUSO during the quarter.

• Additional AU$6.0 million received from exercise of listed options.

Outlook and guidance

• Anticipates one-off costs in the next quarter related to the US licensing transaction and CRO milestone payments.

• Well funded to continue the ACTION3 Phase 3 trial and considering new R&D pipeline investments.

• Ongoing focus on patient recruitment and further licensing in unpartnered territories.